| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics, Preclinical Pharmacology |
National Cancer Institute of Canada Clinical Trials Group, Cancer Clinical Trials Division, Cancer Research Institute, Queen’s University, Kingston, Ontario, K7L 3N6 Canada
Purpose: We looked at the value of three preclinical cancer models, the in vitro human cell line, the human xenograft, and the murine allograft, to examine whether they are reliable in predicting clinical utility.
Experimental Design: Thirty-one cytotoxic cancer drugs were selected. Literature was searched for drug activity in Phase II trials, human xenograft, and mouse allografts in breast, non-small cell lung, ovary, and colon cancers. Data from the National Cancer Institute Human Tumor Cell Line Screen were used to calculate drug in vitro preclinical activity for each cancer type. Phase II activity versus preclinical activity scatter plot and correlation analysis was conducted for each model, by tumor type (disease-oriented approach), using one tumor type as a predictor of overall activity in the other three tumor types combined (compound-oriented approach) and for all four tumor types together.
Results: The in vitro cell line model was predictive for non-small cell lung cancer under the disease-oriented approach, for breast and ovarian cancers under the compound-oriented approach, and for all four tumor types together. The mouse allograft model was not predictive. The human xenograft model was not predictive for breast or colon cancers, but was predictive for non-small cell lung and ovarian cancers when panels of xenografts were used.
Conclusions: These results suggest that under the right framework and when panels are used, the in vitro cell line and human xenograft models may be useful in predicting the Phase II clinical trial performance of cancer drugs. Murine allograft models, as used in this analysis, appear of limited utility.
This article has been cited by other articles:
|
|
 |
|
  D. Lin, A. Watahiki, J. Bayani, F. Zhang, L. Liu, V. Ling, M. D. Sadar, J. English, L. Fazli, A. So, et al. ASAP1, a Gene at 8q24, Is Associated with Prostate Cancer Metastasis Cancer Res., June 1, 2008; 68(11): 4352 - 4359. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Kozuch, C. M. Rocha-Lima, T. Dragovich, H. Hochster, B. H. O'Neil, O. T. Atiq, J. M. Pipas, D. P. Ryan, and H.-J. Lenz Bortezomib With or Without Irinotecan in Relapsed or Refractory Colorectal Cancer: Results From a Randomized Phase II Study J. Clin. Oncol., May 10, 2008; 26(14): 2320 - 2326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. L. Hann, V. C. Daniel, E. A. Sugar, I. Dobromilskaya, S. C. Murphy, L. Cope, X. Lin, J. S. Hierman, D. L. Wilburn, D. N. Watkins, et al. Therapeutic Efficacy of ABT-737, a Selective Inhibitor of BCL-2, in Small Cell Lung Cancer Cancer Res., April 1, 2008; 68(7): 2321 - 2328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Camphausen and P. J. Tofilon Inhibition of Hsp90: A Multitarget Approach to Radiosensitization Clin. Cancer Res., August 1, 2007; 13(15): 4326 - 4330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J. Houghton and C. L. Morton Rational Use of Human Tumor Xenografts for Drug Development Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 77 - 82. [Full Text] [PDF]
|
|
|
|
|
|
L. Varticovski, M. G. Hollingshead, A. I. Robles, X. Wu, J. Cherry, D. J. Munroe, L. Lukes, M. R. Anver, J. P. Carter, S. D. Borgel, et al. Accelerated Preclinical Testing Using Transplanted Tumors from Genetically Engineered Mouse Breast Cancer Models Clin. Cancer Res., April 1, 2007; 13(7): 2168 - 2177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Talmadge, R. K. Singh, I. J. Fidler, and A. Raz Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for Cancer Am. J. Pathol., March 1, 2007; 170(3): 793 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. C. Whiteford, S. Bilke, B. T. Greer, Q. Chen, T. A. Braunschweig, N. Cenacchi, J. S. Wei, M. A. Smith, P. Houghton, C. Morton, et al. Credentialing Preclinical Pediatric Xenograft Models Using Gene Expression and Tissue Microarray Analysis Cancer Res., January 1, 2007; 67(1): 32 - 40. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Carver and P. P. Pandolfi Mouse modeling in oncologic preclinical and translational research. Clin. Cancer Res., September 15, 2006; 12(18): 5305 - 5311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Rubio-Viqueira, A. Jimeno, G. Cusatis, X. Zhang, C. Iacobuzio-Donahue, C. Karikari, C. Shi, K. Danenberg, P. V. Danenberg, H. Kuramochi, et al. An In vivo Platform for Translational Drug Development in Pancreatic Cancer Clin. Cancer Res., August 1, 2006; 12(15): 4652 - 4661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-C. Cutz, J. Guan, J. Bayani, M. Yoshimoto, H. Xue, M. Sutcliffe, J. English, J. Flint, J. LeRiche, J. Yee, et al. Establishment in Severe Combined Immunodeficiency Mice of Subrenal Capsule Xenografts and Transplantable Tumor Lines from a Variety of Primary Human Lung Cancers: Potential Models for Studying Tumor Progression-Related Changes. Clin. Cancer Res., July 1, 2006; 12(13): 4043 - 4054. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Barker, W. E. Burgan, D. J. Carter, D. Cerna, D. Gius, M. G. Hollingshead, K. Camphausen, and P. J. Tofilon In vitro and In vivo Radiosensitization Induced by the Ribonucleotide Reductase Inhibitor Triapine (3-Aminopyridine-2-Carboxaldehyde-Thiosemicarbazone). Clin. Cancer Res., May 1, 2006; 12(9): 2912 - 2918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Sasai, J. T. Romer, Y. Lee, D. Finkelstein, C. Fuller, P. J. McKinnon, and T. Curran Shh pathway activity is down-regulated in cultured medulloblastoma cells: implications for preclinical studies. Cancer Res., April 15, 2006; 66(8): 4215 - 4222. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Sausville, A. M. Burger, O. J. Becher, and E. C. Holland Contributions of human tumor xenografts to anticancer drug development. Cancer Res., April 1, 2006; 66(7): 3351 - 3354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Goffin, S. Baral, D. Tu, D. Nomikos, and L. Seymour Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval Clin. Cancer Res., August 15, 2005; 11(16): 5928 - 5934. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. N. Landen Jr., A. Chavez-Reyes, C. Bucana, R. Schmandt, M. T. Deavers, G. Lopez-Berestein, and A. K. Sood Therapeutic EphA2 Gene Targeting In vivo Using Neutral Liposomal Small Interfering RNA Delivery Cancer Res., August 1, 2005; 65(15): 6910 - 6918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. E. A. Bull, H. Dote, K. J. Brady, W. E. Burgan, D. J. Carter, M. A. Cerra, K. A. Oswald, M. G. Hollingshead, K. Camphausen, and P. J. Tofilon Enhanced Tumor Cell Radiosensitivity and Abrogation of G2 and S Phase Arrest by the Hsp90 Inhibitor 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin Clin. Cancer Res., December 1, 2004; 10(23): 8077 - 8084. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A. Kunz-Schughart, J. P. Freyer, F. Hofstaedter, and R. Ebner The Use of 3-D Cultures for High-Throughput Screening: The Multicellular Spheroid Model J Biomol Screen, June 1, 2004; 9(4): 273 - 285. [Abstract] [PDF]
|
|
|
|
 |
|
 K. Camphausen, K. J. Brady, W. E. Burgan, M. A. Cerra, J. S. Russell, E. E.A. Bull, and P. J. Tofilon Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of {gamma}H2AX foci Mol. Cancer Ther., April 1, 2004; 3(4): 409 - 416. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
